DE69428905D1 - Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels - Google Patents
Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangelsInfo
- Publication number
- DE69428905D1 DE69428905D1 DE69428905T DE69428905T DE69428905D1 DE 69428905 D1 DE69428905 D1 DE 69428905D1 DE 69428905 T DE69428905 T DE 69428905T DE 69428905 T DE69428905 T DE 69428905T DE 69428905 D1 DE69428905 D1 DE 69428905D1
- Authority
- DE
- Germany
- Prior art keywords
- factor viii
- therapeutic agent
- treating
- defect
- activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/120,894 US5576291A (en) | 1993-09-13 | 1993-09-13 | Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency |
PCT/US1994/009613 WO1995007713A1 (en) | 1993-09-13 | 1994-08-26 | Activated factor viii as a therapeutic agent and method of treating factor viii deficiency |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69428905D1 true DE69428905D1 (de) | 2001-12-06 |
DE69428905T2 DE69428905T2 (de) | 2002-05-29 |
Family
ID=22393146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69428905T Expired - Fee Related DE69428905T2 (de) | 1993-09-13 | 1994-08-26 | Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels |
Country Status (10)
Country | Link |
---|---|
US (1) | US5576291A (de) |
EP (1) | EP0719154B1 (de) |
JP (1) | JPH09502714A (de) |
AT (1) | ATE207759T1 (de) |
AU (1) | AU686661B2 (de) |
CA (1) | CA2168332A1 (de) |
DE (1) | DE69428905T2 (de) |
DK (1) | DK0719154T3 (de) |
ES (1) | ES2166783T3 (de) |
WO (1) | WO1995007713A1 (de) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7254894A (en) * | 1993-07-23 | 1995-02-20 | Baxter International Inc. | Activated human factor viii and method of preparation |
US7253262B2 (en) * | 1995-01-19 | 2007-08-07 | Quandrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
US7244824B2 (en) * | 1995-01-19 | 2007-07-17 | Quadrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
GB9501040D0 (en) * | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
SE9501189D0 (sv) * | 1995-03-31 | 1995-03-31 | Pharmacia Ab | Protein formulation |
PT2193809E (pt) | 1999-02-22 | 2015-08-24 | Baxter Int | Formulações de fator viii livres de albumina |
DK1194161T3 (da) * | 1999-07-13 | 2006-02-13 | Biovitrum Ab | Stabile faktor VIII-sammensatninger |
JP4643783B2 (ja) * | 1999-12-24 | 2011-03-02 | 一般財団法人化学及血清療法研究所 | フォンヴィルブランド因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物 |
ATE428439T1 (de) * | 2001-12-21 | 2009-05-15 | Novo Nordisk Healthcare Ag | Flüssige zusammensetzung aus faktor vii polypeptiden |
KR20040065278A (ko) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | 변경된 인자 ⅶ 폴리펩티드의 액체 조성물 |
US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
PT1517698E (pt) | 2002-06-21 | 2014-11-19 | Novo Nordisk Healthcare Ag | Composições sólidas estabilizadas de polipéptidos do fator viia |
BRPI0408439A (pt) * | 2003-03-18 | 2006-04-04 | Novo Nordisk Healthcare Ag | composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético |
US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
MXPA05012476A (es) * | 2003-05-23 | 2006-02-22 | Novo Nordisk Healthcare Ag | Estabilizacion de proteina en solucion. |
WO2004112828A1 (en) * | 2003-06-25 | 2004-12-29 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
DE602004023848D1 (de) * | 2003-07-01 | 2009-12-10 | Novo Nordisk Healthcare Ag | Von factor vii polypeptiden |
JP5653572B2 (ja) | 2003-08-14 | 2015-01-14 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第vii因子ポリペプチドの液状水性医薬組成物 |
US7855274B2 (en) * | 2003-12-03 | 2010-12-21 | University Of Rochester | Recombinant factor VIII having increased specific activity |
WO2005058283A2 (en) * | 2003-12-19 | 2005-06-30 | Novo Nordisk Health Care Ag | Stabilised compositions of factor vii polypeptides |
DE602006018622D1 (de) * | 2005-06-30 | 2011-01-13 | Ge Healthcare Bio Sciences | Nachweisverfahren für die genexpression |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
CN103990116A (zh) | 2007-04-26 | 2014-08-20 | 拜尔健康护理有限责任公司 | 稳定用于冷冻储藏的重组蛋白液体溶液的方法 |
US8183345B2 (en) * | 2007-11-01 | 2012-05-22 | University Of Rochester | Recombinant factor VIII having reduced inactivation by activated protein C |
WO2010054238A1 (en) | 2008-11-07 | 2010-05-14 | Baxter International Inc. | Factor viii formulations |
US20110046060A1 (en) | 2009-08-24 | 2011-02-24 | Amunix Operating, Inc., | Coagulation factor IX compositions and methods of making and using same |
DK3178835T3 (da) | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
US20130017997A1 (en) * | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
BR112014020694A2 (pt) | 2012-02-15 | 2018-05-08 | Amunix Operating Inc. | proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a |
AU2013204636B2 (en) | 2012-02-15 | 2016-04-14 | Bioverativ Therapeutics Inc. | Recombinant Factor VIII proteins |
TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子viii-xten融合物及其用途 |
CN108139383A (zh) * | 2015-05-06 | 2018-06-08 | 普雷西恩医药控股有限责任公司 | 用于检测fviii抑制剂的新型自动筛选方法的研究 |
TWI741992B (zh) | 2015-08-03 | 2021-10-11 | 美商百歐維拉提夫治療公司 | 因子ix融合蛋白以及其製備及使用方法 |
MX2020012397A (es) | 2018-05-18 | 2021-04-12 | Bioverativ Therapeutics Inc | Metodos de tratamiento de la hemofilia a. |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2460305A2 (fr) * | 1979-06-29 | 1981-01-23 | Merieux Inst | Procede de preparation d'un concentre de facteur viii |
US4386068A (en) * | 1980-02-26 | 1983-05-31 | Cutter Laboratories, Inc. | Antihemophilic factor concentrate and method for preparation |
AT369263B (de) * | 1980-08-27 | 1982-12-27 | Immuno Ag | Verfahren zur herstellung eines faktor viii(ahf) -hochkonzentrates |
US5101016A (en) * | 1983-03-31 | 1992-03-31 | Scripps Clinic And Research Foundation | Factor VIII coagulant polypeptides and monoclonal antibodies to them |
US4649132A (en) * | 1983-03-31 | 1987-03-10 | Scripps Clinic And Research Foundation | Treatment of Factor VIII inhibitors |
CA1341506C (en) * | 1983-03-31 | 2006-06-06 | Theodore S. Zimmerman | Factor viii coagulant polypeptides and monoclonal antibodies to them |
US4657894A (en) * | 1983-03-31 | 1987-04-14 | Scripps Clinic & Research Foundation | New factor VIII coagulant polypeptides |
US4857635A (en) * | 1983-03-31 | 1989-08-15 | Scripps Clinic And Research Foundation | Factor VIII coagulant polypeptides and monoclonal antibodies tof them |
US4757006A (en) * | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4508709A (en) * | 1983-12-05 | 1985-04-02 | Armour Pharmaceutical Company | Process for purifying factor VIII:C |
US4965199A (en) * | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
DK525384D0 (da) * | 1984-11-05 | 1984-11-05 | Nordisk Insulinlab | Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat |
SE8501050D0 (sv) * | 1985-03-05 | 1985-03-05 | Kabivitrum Ab | Biologically active fragments of human antihemophilic factor and method for preparation thereof |
ES8801674A1 (es) * | 1985-04-12 | 1988-02-16 | Genetics Inst | Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante. |
US4769336A (en) * | 1985-05-24 | 1988-09-06 | Scripps Clinic And Research Foundation | Treatment of factor VIII inhibitors |
US4758657A (en) * | 1985-07-11 | 1988-07-19 | Armour Pharmaceutical Company | Method of purifying Factor VIII:C |
CA1331157C (en) * | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
US4980456A (en) * | 1987-04-06 | 1990-12-25 | Scripps Clinic And Research Foundation | Recombinant factor VIIIC derived fragments |
IE69026B1 (en) * | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
US4795806A (en) * | 1987-07-16 | 1989-01-03 | Miles Laboratories, Inc. | Phospholipid affinity purification of Factor VIII:C |
US4981951A (en) * | 1988-04-14 | 1991-01-01 | Miles Inc. | Lectin affinity chromatography of factor VIII |
US5149687A (en) * | 1991-04-01 | 1992-09-22 | United Technologies Corporation | Method for making oriented bismuth and thallium superconductors comprising cold pressing at 700 MPa |
-
1993
- 1993-09-13 US US08/120,894 patent/US5576291A/en not_active Expired - Fee Related
-
1994
- 1994-08-26 JP JP7509198A patent/JPH09502714A/ja not_active Ceased
- 1994-08-26 DK DK94926591T patent/DK0719154T3/da active
- 1994-08-26 AT AT94926591T patent/ATE207759T1/de not_active IP Right Cessation
- 1994-08-26 WO PCT/US1994/009613 patent/WO1995007713A1/en active IP Right Grant
- 1994-08-26 DE DE69428905T patent/DE69428905T2/de not_active Expired - Fee Related
- 1994-08-26 AU AU76380/94A patent/AU686661B2/en not_active Ceased
- 1994-08-26 CA CA002168332A patent/CA2168332A1/en not_active Abandoned
- 1994-08-26 EP EP94926591A patent/EP0719154B1/de not_active Expired - Lifetime
- 1994-08-26 ES ES94926591T patent/ES2166783T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0719154A1 (de) | 1996-07-03 |
AU686661B2 (en) | 1998-02-12 |
EP0719154B1 (de) | 2001-10-31 |
DE69428905T2 (de) | 2002-05-29 |
CA2168332A1 (en) | 1995-03-23 |
WO1995007713A1 (en) | 1995-03-23 |
AU7638094A (en) | 1995-04-03 |
US5576291A (en) | 1996-11-19 |
ES2166783T3 (es) | 2002-05-01 |
JPH09502714A (ja) | 1997-03-18 |
ATE207759T1 (de) | 2001-11-15 |
DK0719154T3 (da) | 2001-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69428905D1 (de) | Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels | |
ATE275383T1 (de) | Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen | |
ATE280577T1 (de) | Oxa-säuren und verwandte verbindungen zur behandlung von störungen der haut | |
ATE342278T1 (de) | Verfahren zur behandlung von diabetes mittels kgf | |
DE69625691D1 (de) | Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten | |
DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
DE60028573D1 (de) | Behandlung und zusammensetzungen zur erzielung eines hautalterungsschutzes durch corneum protease aktivatoren | |
DE59306276D1 (de) | Verfahren und anordnung zur therapie von gewebe mit ultraschall | |
DE69433742D1 (de) | Bmp-10 zusammensetzungen | |
ATE444086T1 (de) | Therapeutische zusammensetzungen und verfahren zur behandlung von periodontitis mit entzündunshemmenden mitteln | |
LV12558A (lv) | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate | |
DE69807115D1 (de) | Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms | |
ATE222488T1 (de) | Verwendung von anti-vegf-mitteln zur behandlung der endometriose | |
ATE99932T1 (de) | Verwendung von pyrrolicloncarbonsaeurealkylestern zur herstellung eines arzneimittels zur behandlung von ichtyosis. | |
ATE119147T1 (de) | Verbindungen und zusammensetzungen zur anwendung bei methoden zur behandlung und prophylaxe von pneumocystis carinii pneumonia und anderen krankheiten. | |
ATE190843T1 (de) | Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten | |
DE69625682D1 (de) | Verfahren zur behandlung von entzündungen und zusammensetzungen dafür | |
DE69721824D1 (de) | Verwendung von carbonanhydrase-hemmern zur behandlung von makulär-ödemen | |
DE69626311D1 (de) | Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür | |
ATE143804T1 (de) | Zusammensetzung zur behandlung von mastitis und metritis | |
DE69523506D1 (de) | Verwendung eines Enzyms zur Herstellung eines Mittels für die Behandlung und/oder Prophylaxe von Coccidiose | |
ATE294582T1 (de) | Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs | |
ATE219372T1 (de) | Verfahren zur behandlung von blutungsstorungen | |
DE60042171D1 (de) | Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen | |
DE69403372D1 (de) | Poliermittel und Verfahren zur Behandlung von calciumcarbonathaltigen Oberflachen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |